Ami Shah, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Looking this up.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A49984 · Current
Licensed to practise in California · since 1991 · expires 2026-12-31 · University of North Carolina at Chapel Hill.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$2,144 in 2020
Medicaid paid $2,144 for 15 billed services this clinician did in 2020, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $2,144 |
| 2020 | 15 | 1 | 12 | $2,144 |
| 2019 | 15 | 1 | 13 | $2,016 |
See the largest Medicaid services in earlier years
2019
| Long return visit (40+ min) | 15 | $2,016 |
Money from drug and device companies
$80 in 2025
| 2025 | 1 | 1 | None | $80 |
| 2024 | 4 | 6 | $42 | $364 |
| 2023 | 2 | 3 | $485 | $602 |
| 2022 | 1 | 1 | $3,638 | $3,638 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pharming Healthcare | Ruconest | $80 | 1 payment
|
See the published payment
| Pharming Healthcare | Meals · 2025-05-08 | Ruconest | $80 |
See earlier years (2024, 2023, 2022)
2024: $364
| Sobi | Gamifant | $185 | 3 payments
|
| bluebird bio | None | $105 | 1 payment
|
| ADMA BioManufacturing | None | $42 | 1 payment
|
| Vertex Pharmaceuticals | None | $32 | 1 payment
|
2023: $602
| Vertex Pharmaceuticals | None | $485 | 1 payment
|
| bluebird bio | Zynteglo | $117 | 2 payments
|
2022: $3,638
| Vertex Pharmaceuticals | None | $3,638 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Vertex Pharmaceuticals Incorporated · A Phase 1/2 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2021 | Their institution | $1,135,841 |
| Vertex Pharmaceuticals Incorporated · A Phase 1/2 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2022 | Their institution | $943,674 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1/2/3 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2024 | Their institution | $440,789 |
| Genetix Biotherapeutics Inc · Long-Term Follow-Up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product · 2025 | Their institution | $140,484 |
| bluebird bio, Inc. · Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product · 2024 | Their institution | $139,582 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1/2/3 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2025 | Their institution | $119,374 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 1/2/3 Study of the Safety and Efficacy of A Single Dose of Autologous Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem and Progenitor Cells (Hhspcs) in Subjects With Transfusion-Dependent Beta-Thalassemia · 2023 | Their institution | $90,540 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Long-Term Follow-Up Study of Subjects With B-Thalassemia Or Sickle Cell Disease Treated With Autologous Crispr-Cas9 Modified Hematopoietic Stem Cells · 2025 | Their institution | $67,333 |
| bluebird bio, Inc. · A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects < 17 Years of Age With Cerebral Adrenoleukodystrophy (Cald) · 2023 | Their institution | $62,510 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Long-Term Follow-Up Study of Subjects With B-Thalassemia Or Sickle Cell Disease Treated With Autologous Crispr-Cas9 Modified Hematopoietic Stem Cells · 2024 | Their institution | $16,725 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2023 | Their institution | $11,306 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2025 | Their institution | $9,053 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Long-Term Follow-Up Study of Subjects With B-Thalassemia Or Sickle Cell Disease Treated With Autologous Crispr-Cas9 Modified Hematopoietic Stem Cells · 2023 | Their institution | $4,682 |
| bluebird bio, Inc. · A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects < 17 Years of Age With Cerebral Adrenoleukodystrophy (Cald) · 2024 | Their institution | $2,130 |
| Hoffmann-La Roche Limited · Tamiflu Pediatric Ic Study Pdco Request · 2019 | Their institution | $584 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2021 | Their institution | $340 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Safety and Efficacy Study Evaluating Ctx001 in Subjects With Severe Sickle Cell Disease · 2022 | Their institution | $276 |
Professional record
- NPI
- 1245321595
- Licence
- CA A49984California A49984: Current · expires 2026-12-31
- Trained
- North Carolina Medical School, 1990
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A499840
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-09-28
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.